Published On: Wed, Oct 19th, 2016

Latest Analyst Reports On Marinus Pharmaceuticals, Inc.


Recently stock market analysts have updated their consensus ratings on shares of Marinus Pharmaceuticals, Inc. (MRNS).

Most recent broker ratings

09/30/2016 – Marinus Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 3 price target on the stock.

06/28/2016 – Marinus Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Stifel Nicolaus.

06/14/2016 – Marinus Pharmaceuticals, Inc. was downgraded to “perform” by analysts at Oppenheimer.

06/14/2016 – Marinus Pharmaceuticals, Inc. was downgraded to “sector perform” by analysts at RBC Capital. They now have a USD 2 price target on the stock.

05/18/2015 – Marinus Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Janney Montgomery Scott. They now have a USD 20 price target on the stock.

05/13/2015 – Marinus Pharmaceuticals, Inc. was upgraded to “buy” by analysts at Zacks. They now have a USD 9 price target on the stock.

08/26/2014 – JMP Securities began new coverage on Marinus Pharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 14 price target on the stock.

Marinus Pharmaceuticals, Inc. has a 50 day moving average of 1.71 and a 200 day moving average of 2.99. The stock’s market capitalization is 27.12M, it has a 52-week low of 1.19 and a 52-week high of 9.08.

The share price of the company (MRNS) was up +1.46%, with a high of 1.43 during the day and the volume of Marinus Pharmaceuticals, Inc. shares traded was 242896.

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.